Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 901-907

  Shannon, Harlan E ^a   Hart, John C ^a   Bymaster, Frank P ^a   Calligaro, David O ^a   Delapp, Neil W ^a   Mitch, Charles H ^a   Ward, John S ^a   Fink Jensen, Anders ^b   Sauerberg, Per ^b   Jeppesen, Lone ^b   Sheardown, Malcolm J ^b   Swedberg, Michael D B ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ACECLIDINE; BENZATROPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MILAMELINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OXOTREMORINE; PHYSOSTIGMINE; PILOCARPINE; SABCOMELINE; SCOPOLAMINE; TALSACLIDINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; XANOMELINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ELECTRIC SHOCK; INSTRUMENTAL CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CHOLINESTERASE INHIBITORS; CONDITIONING, OPERANT; DEPRESSION, CHEMICAL; DIAZEPAM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MUSCARINIC AGONISTS; PILOCARPINE; RATS; RATS, INBRED F344; RECEPTORS, MUSCARINIC; SCOPOLAMINE; SUCCINIMIDES;

EID: 0032839566     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Abood LG and Biel JH (1962) Anticholinergic psychotomimetic agents. Int Rev Neurobiol 4:217-273.
2. Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321-329.
3. 1-selective muscarinic agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 54:465-473.
4. Bolam JP, Francis CM and Henderson Z (1991) Cholinergic input to dopaminergic neurons in the substantia nigra: A double immunocytochemical study. Neuroscience 41:1035-1044.
5. 1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. J Med Chem 40:4265-4280.
6. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp NW, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink-Jensen A and Sauerberg P (1998a) Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 79:179-190.
7. Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MDB, Sauerberg P and Fink-Jensen AJ (1998b) Unexpected antipsychotic-like activity with the muscarinic agonist PTAC. Eur J Pharmacol 356:109-119.
8. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, Buelke-Sam JL, Bodick NC, Farde L, Sheardown MJ, Olesen PH, Hansen KT, Suzdak PD, Swedberg MDB, Sauerberg P and Mitch CH (1997) Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 40:158-170.
9. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 269:282-289.
10. Carlsson A, Hansson LL, Waters N and Carlsson ML (1997) Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci 61:75-94.
11. Chalmers RK and Erickson CK (1964) Central cholinergic blockade of the conditioned avoidance response in rats. Psychopharmacologia 6:31-41.
12. Creese I, Burt D and Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (Wash DC) 192:481-483.
13. Cummings JL, Gorman DG and Shapira J (1993) Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 33:536-541.
14. Davidson AB and Weidley E (1976) Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats. Life Sci 18:1279-1284.
15. Davis KL and Berger PA (1978) Pharmacological investigations of the cholinergic imbalance hypothesis of movement disorders and psychosis. Biol Psychiatry 12: 23-49.
16. Edelstein P, Schultz JR, Hirschowitz J, Kanter DR and Garver DL (1981) Physostigmine and lithium in the schizophrenias. Am J Psychiatry 138:1078-1081.
17. Ensinger HA, Doods HN, Immel-Sehr AR, Kuhn FJ, Lambrecht G, Mendla KD, Müller RE, Mutschler E, Sagrada A, Walther G and Hammer R (1993) WAL 2014: A muscarinic agonist with preferential neuron-stimulating properties. Life Sci 52:473-480.
18. Garcia-Rill E, Biederman JA, Chambers T, Skinner RD, Mrak RE, Husain M and Karson CN (1995) Mesopontine neurons in schizophrenia. Neuroscience 66:321-335.
19. Gorman DG, Read S and Cummings JL (1993) Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 6:229-234.
20. Gronier B and Rasmussen K (1998) Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: An in vivo electrophysiological study in the rat. Br J Pharmacol 124:455-464.
21. Kaufer DI, Cummings JL and Christine D (1996) Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open label study. J Geriatr Psychiatry Neurol 9:1-6.
22. Kuribara H and Tadokoro S (1985) Effects of psychoactive drugs on conditioned avoidance response in Mongolian gerbils (Meriones unguiculatus): Comparison with Wistar rats and dd mice. Pharmacol Biochem Behav 23:1013-1018.
23. 1 receptors. J Pharmacol Exp Ther 283:1059-1068.
24. Moore NA, Tye NC, Axton MS and Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551.
25. Niemegeers CJE, Verbruggen FJ and Janssen PAJ (1969) The influence of various neuroleptic drugs on shock avoidance responding in rats. Psychopharmacologia 16:161-174.
26. Pfeiffer CC and Jenny EH (1957) The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci 66:753-764.
27. Philippens IHCHM, Melchers BPC and Wolthuis OL (1992) Active avoidance behavior in guinea pigs: Effects of physostigmine and scopolamine. Pharmacol Biochem Behav 42:285-289.
28. Richards MH and van Giersbergen PLM (1995) Human muscarinic receptors expressed in A9L and CHO cells: Activation by full and partial agonists. Br J Pharmacol 114:1241-1249.
29. Sauerberg P, Jeppesen L, Olesen PH, Rasmussen T, Swedberg MDB, Sheardown MJ, Fink-Jensen A, Thomsen C, Thogersen H, Ward JS, Calligaro DO, DeLapp NW, Bymaster FP and Shannon HE (1998) Muscarinic agonists with antipsychotic-like activity: Structure activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J Med Chem 41:4378-4384.
30. 1 selective muscarinic agonists: Synthesis and structure-activity relationships of 3-(1,2,5-thiadizolyl)-1,2,5,6-tetrahydro-1-methylpvridines. J Med Chem 35:2274-2283.
31. Schwarz RD, Davis RE, Jaen JC, Spencer CJ, Tecle H and Thomas AJ (1993) Characterization of muscarinic agonists in recombinant cell lines. Life Sci 52:465-472.
32. Sedman AJ, Bockbrader H and Schwarz RD (1995) Preclinical and phase I clinical characterization of CI979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci 58:877-882.
33. 1 muscarinic receptor agonist. J Pharmacol Exp Ther 269:271-281.
34. Tandon R and Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiatry 46:745-753.
35. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH and Goodson J (1991) Muscarinic cholinergic hyperactivity in schizophrenia: Relationship to positive and negative symptoms. Schizophr Res 4:23-30.
36. Verhave T, Owen JE and Robbins EB (1957) Effects of secobarbital and pentobarbital on escape and avoidance behavior. Psychol Rep 3:421-428.
37. White KG and Cummings JL (1996) Schizophrenia and Alzheimer's disease: Clinical and pathophysiologic analogies. Compr Psychiatry 37:188-195.
38. Yeomans JS (1995) Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropharmacology 12:3-16.
39. Yeomans JS, Mathur A and Tampakeras M (1993) Rewarding brain stimulation: Role of tegmental cholinergic neurons that activate dopamine neurons. Behav Neurosci 107:1077-1087.